
					Posted by Charlotte Bryant on Apr 14th, 2019 // Comments off Zacks Investment Research upgraded shares of ReNeuron Group (OTCMKTS:RNUGF) from a sell rating to a hold rating in a report issued on Thursday, Zacks.com reports. According to Zacks, “ReNeuron Group plc is involved in the development of cell-based therapies. Its therapeutic candidate is CTX stem cell therapy for the treatment of patients left disabled by the effects of a stroke which are in clinical development phase. ReNeuron Group plc is headquartered in Pencoed, the United Kingdom.   “OTCMKTS:RNUGF opened at $3.04 on Thursday. The stock has a market capitalization of $96.20 million, a price-to-earnings ratio of -304.00 and a beta of -78.39. ReNeuron Group has a 52 week low of $0.57 and a 52 week high of $3.19.  ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia.See Also: What is a Derivative?Get a free copy of the Zacks research report on ReNeuron Group (RNUGF)For more information about research offerings from Zacks Investment Research, visit Zacks.comReceive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.Telenor ASA (TELNY) Upgraded at Zacks Investment ResearchAnalysts Expect SP Plus Corp (SP) to Announce $0.45 Earnings Per Share